<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04642391</url>
  </required_header>
  <id_info>
    <org_study_id>16007</org_study_id>
    <nct_id>NCT04642391</nct_id>
  </id_info>
  <brief_title>Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis</brief_title>
  <official_title>Defining the Incidence of and Mechanisms Underlying Adrenal Insufficiency in Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to define the prevalence and potential pathophysiologic mechanisms underlying&#xD;
      relative adrenal insufficiency (RAI) in outpatients with decompensated cirrhosis. Patients&#xD;
      will be followed prospectively for up to two years to determine incidence of RAI, whether RAI&#xD;
      represents a permanent or dynamic physiologic state in cirrhosis, and to determine whether&#xD;
      RAI in this setting is associated with important clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>RAI prevalence</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Cholesterol Esterification Percentage</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 month Cholesterol Esterification Percentage</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month Cholesterol Esterification Percentage</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 month Cholesterol Esterification Percentage</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 month Cholesterol Esterification Percentage</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline 17-OH Progesterone Level</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 month 17-OH Progesterone Level</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month 17-OH Progesterone Level</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 month 17-OH Progesterone Level</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 month 17-OH Progesterone Level</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline ACTH level</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 month ACTH level</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month ACTH level</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 month ACTH level</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 month ACTH level</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline IL-1 Level</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 month IL-1 Level</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month IL-1 Level</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 month IL-1 Level</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 month IL-1 Level</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Plasma Renin Activity</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 month Plasma Renin Activity</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month Plasma Renin Activity</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 month Plasma Renin Activity</measure>
    <time_frame>18 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 month Plasma Renin Activity</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline serum normetanephrine level</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 month serum normetanephrine level</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month serum normetanephrine level</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 month serum normetanephrine level</measure>
    <time_frame>18 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 month serum normetanephrine level</measure>
    <time_frame>24 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline 11-deoxycortisol level</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 month 11-deoxycortisol level</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month 11-deoxycortisol level</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 month 11-deoxycortisol level</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 month 11-deoxycortisol level</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline HDL level</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 month HDL level</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month HDL level</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 month HDL level</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 month HDL level</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline IL-6 level</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 month IL-6 level</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month IL-6 level</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 month IL-6 level</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 month IL-6 level</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline IL-10 level</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 month IL-10 level</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month IL-10 level</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 month IL-10 level</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 month IL-10 level</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline TNFa level</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>6 month TNFa level</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>12 month TNFa level</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>18 month TNFa level</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24 month TNFa level</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized Incidence of RAI</measure>
    <time_frame>over two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day transplant-free survival</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day transplant-free survival</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month transplant-free survival</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year transplant-free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 year transplant-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day new or worsened portal hypertensive decompensation</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90 day new or worsened portal hypertensive decompensation</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 month new or worsened portal hypertensive decompensation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year new or worsened portal hypertensive decompensation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 year new or worsened portal hypertensive decompensation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day unplanned hospitalization</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90 day unplanned hospitalization</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 month unplanned hospitalization</measure>
    <time_frame>6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year unplanned hospitalization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 year unplanned hospitalization</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Adrenal Insufficiency</condition>
  <arm_group>
    <arm_group_label>RAI</arm_group_label>
    <description>Subjects will be diagnosed with relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol &lt;9mcg/dL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-RAI</arm_group_label>
    <description>Subjects will have not have relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol &gt;= 9mcg/dL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cosyntropin</intervention_name>
    <description>Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis</description>
    <arm_group_label>Non-RAI</arm_group_label>
    <arm_group_label>RAI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Decompensated cirrhosis (cirrhosis + at least 1 clinically-significant decompensation&#xD;
        including ascites/hepatic hydrothorax, spontaneous bacterial peritonitis, variceal bleed,&#xD;
        hepatic encephalopathy)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;= 18y&#xD;
&#xD;
          -  Diagnosis of cirrhosis by biopsy or compatible clinical picture&#xD;
&#xD;
          -  Experienced at least one portal decompensating event in the past and currently have a&#xD;
             Child-Pugh B or C classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Not been treated with medication known to affect the adrenal axis within the past 4&#xD;
             weeks (oral or IV steroids, ketoconazole, etomidate)&#xD;
&#xD;
          -  Hospitalized at time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brian J Wentworth, MD</last_name>
    <phone>4342432109</phone>
    <email>bw8xz@hscmail.mcc.virginia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Brian J Wentworth, MD</last_name>
      <phone>434-243-2109</phone>
      <email>bw8xz@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Zachary H Henry, MD</last_name>
      <phone>434-243-2718</phone>
      <email>zhh6z@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Helmy Siragy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Caldwell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Curtis Argo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Brian Wentworth, MD</investigator_full_name>
    <investigator_title>Transplant Hepatology Fellow</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Adrenal Insufficiency</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cosyntropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

